The cause or causes of the nearly 100 autoimmune disorders have in most cases not been specifically defined, although much information is available on mechanisms. First observations on a possible relationship to medications were made in 1945 when an association was noted between a lupuslike syndrome in a patient receiving sulfadiazine. There were many subsequent reports implicating sulfonamides and penicillin, again with systemic lupuslike features. In 1953, hydralazine given in the treatment of hypertension was also reported to be related to a lupuslike syndrome. These observations by Morrow et al. (1) were really the first substantially documented observations; the earlier observations were on case reports, thus leaving open the possibility that these could have been cases of idiopathic systemic lupus. The drug procainamide, which is used for the treatment of cardiac arrhythmias (2) , has the best documented association with drugrelated lupus (DRL) syndromes. The anticonvulsant drugs were first associated with such presentations in 1957 (3) . Since The disease symptoms are somewhat milder, and as the potential association with a drug or medication is noted, the symptoms can often be aborted when the offending drug is stopped. Clinically, the skin, renal, and neurologic features of SLE are relatively rare in DRL. Table 2 lists the frequency of clinical and laboratory features in the two types of lupus disorders.
Laboratory Changes
Clearly, at least until now, the "ticket of admission" to diagnosis has been a positive antinuclear antibody (ANA). The laboratory profiles of idiopathic SLE and DRL are listed in Table 2 . The ANA staining pattern is usually the diffuse type, and antibodies to singlestranded DNA (ssDNA) as opposed to double-stranded DNA (dsDNA) are seen with DRL. Antibodies to histones are seen very frequently with DRL and there has been considerable study of these antibodies to different histone proteins. With different drugs, there appears to be a broad array of autoantigenic epitopes to the individual histone and histone complexes. Recent work suggests that a switch from IgM to IgG isotype may precede the development of lupuslike syndromes, particularly in patients taking procainamide (5 It is appropriate to make some specific comments relative to some drugs and biologic agents. Minocycline hydrochloride, a (6) and to the present time, an additional 76 cases have been published. Most of these cases appear to occur in young women, perhaps because they are most often being treated for acne.
A polyarthralgia or polyarthritis affecting the small joints, rather similar to rheumatoid arthritis, is a common feature. The duration of therapy has ranged from a few weeks to 10 years. Another feature of DRL is that not all of the patients have a positive ANA; antibodies to dsDNA, phospholipids and to p-ANCA antibodies have been reported (7). The relationship of lupus syndromes and scleroderma to silica has been confirmed by studies in miners in Silesia (15) . Data presented at this meeting have shown an association of scleroderma in South Carolina to solvent-oriented hobbies (16) .
There is little need to provide any details here about the controversy relating to injection or implantation of paraffin and silicone in breast augmentation procedures. Where large-scale studies have been performed, definitive associations have not been shown.
Interpretation is made even more difficult by the wide range of symptoms reported; the general term "siliconosis" has been invoked.
A detailed study of the two large confirmed environmental outbreaks is recommended to the reader. The first of these was the outbreak in Spain in 1981 in over 35,000 people related to the ingestion of denatured rapeseed oil (10) . Again, what is striking is the very long list of nonspecific symptoms-fever, malaise, lung involvement, muscle/joint involvement, and the eventual appearance of Environmental Health Perspectives * Vol 107, Supplement 5 * October 1999 sclerodermalike disease, lupuslike disease, peripheral neuropathies, and Sj6gren-like syndromes. Long-term follow-up has shown the persistence of disease in about 10% of those originally affected. Similarly, the eosinophilia myalgia syndrome first described by Edison et al. (11) in 1989 had a similar range of symptoms and was characterized by a marked increase in peripheral blood eosinophils and muscle disease confirmed by muscle biopsy. On follow-up, many of these patients developed a scleroderma-like condition, lung involvement, and sensory neuropathies, again similar to that in the Spanish outbreak. ANAs and antihistone antibodies were present, but antibodies to different nuclear and cytoplasmic antigens were negative.
It is of note that a number of other compounds can also give rise to an eosinophilic myalgia or myositis syndrome. These include Tranilast (a mast cell stabilizer), sulfisoxazole, penicillamine, simethadine, phenytoin and alcohol.
Heavy Metals
It is well known that chronic exposure to a number of metals such as mercury, gold, and cadmium can induce autoantibodies and clinically an immune complex-mediated glomerulonephritis. Most of these observations have been in animals, although there are now some reports in humans. The latter have occurred mainly in patients exposed to mercury through the use of skin-lightening creams (17 Another factor that has to be considered in humans and experimental animals is the possible inciting or potentiating effect of infectious agents. Myxoviruses, retroviruses, measles, rubella, parainfluenza, Epstein-Barr, Type C oncarnoviruses, and Type C retroviruses could all play a role and must be considered when looking at mechanisms of cross-reactive antigens (20) . Among the bacteria under consideration are streptococcal cell wall products, lipopolysaccharides, and adjuvant components.
The genetics of the immune system in autoimmune diseases and phenomena is increasingly complex. It would appear that for any one compound or environmental agent, genetic factors may differ. There is also the added complication of the genetics of the host response as manifested in the expression of different disease states. However complicated, such studies should continue and be supported, as can be seen from the example of the specific genetic association of HLA-DP.B1 glutamate in beryllium-exposed workers (21) . The National Research Council established a program in 1991 to define biologic markers in immunotoxicology. This and many other aspects of the National Toxicology Program should be strongly supported and is a recommendation ofthis conference.
